Reversal of bone marrow fibrosis in idiopathic myelofibrosis after treatment with α-interferon

被引：0
作者：
Domingues, MA
Hæpers, ATC
Massaut, IHB
Vassallo, J
Lorand-Metze, I
机构：
[1] State Univ Campinas, Fac Med, Campinas, SP, Brazil
[2] Hematol Hemotherapy Ctr Florianopolis, Florianopolis, SC, Brazil
来源：
HAEMATOLOGICA | 1998年 / 83卷 / 12期
关键词：
myelofibrosis; children; interferon; treatment;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A 14-year-old boy presenting with primary myelofibrosis (MMM) was treated with alpha-interferon (IFN). After 6 months his spleen was no longer palpable and blood counts had returned to normal. A reversal of bone marrow fibrosis was histologically documented. Although improvement in symptoms and blood counts has been reported, this is only the second description of reversal of bone marrow fibrosis in MMM after treatment.
引用
收藏
页码：1124 / 1125
页数：2
相关论文
共 50 条
  • [21] Dengue fever and bone marrow myelofibrosis
    Qing, Xin
    Sun, Nora
    Yeh, James
    Yue, Changjun
    Cai, Junchao
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2014, 97 (02) : 208 - 210
  • [22] BONE-MARROW SCINTIGRAPHY IN MYELOFIBROSIS
    RAIN, JD
    NAJEAN, Y
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1993, 35 (01): : 101 - 102
  • [23] Reversal of fortune? Respiratory failure after bone marrow transplantation
    Bojko, T
    Notterman, DA
    CRITICAL CARE MEDICINE, 1999, 27 (06) : 1061 - 1062
  • [24] Interferon gamma-1b in the treatment of idiopathic pulmonary fibrosis
    Pacanowski, MA
    Amsden, GW
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (10) : 1678 - 1686
  • [25] MULTIPLE-MYELOMA WITH BONE-MARROW BIOPSY FEATURES SIMULATING CONCOMITANT CHRONIC IDIOPATHIC MYELOFIBROSIS
    SCHMIDT, U
    RUWE, M
    LEDER, LD
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1995, 37 (02): : 159 - 163
  • [26] Resident bone marrow macrophages in idiopathic (primary) myelofibrosis (IMF): a histochemical and morphometric study on sequential trephine biopsies
    Thiele, J
    Kvasnicka, HM
    Boeltken, B
    LEUKEMIA RESEARCH, 1999, 23 (11) : 983 - 985
  • [27] Periostin and bone marrow fibrosis
    Eijiro Oku
    Taisuke Kanaji
    Yuka Takata
    Koichi Oshima
    Ritsuko Seki
    Satoshi Morishige
    Rie Imamura
    Korenori Ohtsubo
    Michitoshi Hashiguchi
    Koichi Osaki
    Kazuaki Yakushiji
    Kohji Yoshimoto
    Hideaki Ogata
    Hirofumi Hamada
    Kenji Izuhara
    Michio Sata
    Takashi Okamura
    International Journal of Hematology, 2008, 88 : 57 - 63
  • [28] Periostin and bone marrow fibrosis
    Oku, Eijiro
    Kanaji, Taisuke
    Takata, Yuka
    Oshima, Koichi
    Seki, Ritsuko
    Morishige, Satoshi
    Imamura, Rie
    Ohtsubo, Korenori
    Hashiguchi, Michitoshi
    Osaki, Koichi
    Yakushiji, Kazuaki
    Yoshimoto, Kohji
    Ogata, Hideaki
    Hamada, Hirofumi
    Izuhara, Kenji
    Sata, Michio
    Okamura, Takashi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (01) : 57 - 63
  • [29] Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?
    Matteo Molica
    Alessandra Serrao
    Roberta Saracino
    Irene Zacheo
    Christof Stingone
    Giuliana Alimena
    Massimo Breccia
    Annals of Hematology, 2014, 93 : 1951 - 1952
  • [30] Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis
    Oh, Stephen T.
    Verstovsek, Srdan
    Gupta, Vikas
    Platzbecker, Uwe
    Devos, Timothy
    Kiladjian, Jean-Jacques
    McLornan, Donal P.
    Perkins, Andrew
    Fox, Maria Laura
    McMullin, Mary Frances
    Mead, Adam J.
    Egyed, Miklos
    Mayer, Jiri
    Sacha, Tomasz
    Kawashima, Jun
    Huang, Mei
    Strouse, Bryan
    Mesa, Ruben
    EJHAEM, 2024, 5 (01): : 105 - 116
12345